PATENT CLAIM ANALYSIS

Application Number: 15908644
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "008800"]

Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.

Claim (Index 30):
The method of  claim 29 , wherein the patient has, or is at risk of having, a disease characterized by unwanted angiogenesis.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 88.0
- Lexical Diversity: 1.24324
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14112620', '15360588', '12434598', '11982738', '13447091']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8050067189320897
- 35 USC 102 Novelty (BERT): 0.5662692927881726
- Combined Prediction Score: 0.7811329763176981
- Mean Citation Score: 384.346086
- Max Citation Score: 669.2701400000002
- Similarity Product: 323.1209355039092

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test